| Followers | 52 |
| Posts | 14371 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Friday, November 15, 2024 10:59:35 AM
I like you had been looking to salvage this investment for $5, but that is exceedingly looking improbable, at least for the near future. As far as your question about valuation/cash here is an AI comment: (bold my emphasis)
AI Overview
No, it's not normal for a company to be valued for less than its cash, but it can happen:
When it does happen
A company's market capitalization is lower than its cash holdings minus liabilities when it trades below cash. This can indicate that the market is pessimistic about the company's future, or that investors think it's worth more if liquidated.
When it's more likely to happen
It's more common in bear markets, or in industries with high cash burn rates and uncertain returns, like biotechnology and IT.
When it can be a good opportunity
However, a stock trading below cash can also be a good opportunity if the pessimism isn't justified. This could be if the company is in the early stages of a turnaround, or if investors are being overly skeptical of a drug or technology it's developing.
When it can signal impending failure
A stock trading below cash can also signal impending failure if the company can't raise more capital before its cash runs out, or if it has significant liabilities that aren't clear on the balance sheet.
AI Overview
No, it's not normal for a company to be valued for less than its cash, but it can happen:
When it does happen
A company's market capitalization is lower than its cash holdings minus liabilities when it trades below cash. This can indicate that the market is pessimistic about the company's future, or that investors think it's worth more if liquidated.
When it's more likely to happen
It's more common in bear markets, or in industries with high cash burn rates and uncertain returns, like biotechnology and IT.
When it can be a good opportunity
However, a stock trading below cash can also be a good opportunity if the pessimism isn't justified. This could be if the company is in the early stages of a turnaround, or if investors are being overly skeptical of a drug or technology it's developing.
When it can signal impending failure
A stock trading below cash can also signal impending failure if the company can't raise more capital before its cash runs out, or if it has significant liabilities that aren't clear on the balance sheet.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
